GeneDx (NASDAQ:WGS) Reaches New 1-Year High - Still a Buy?

Key Points

• GeneDx Holdings Corp. reached a new 52-week high of $135.39 on Monday, closing at $134.75 with a trading volume of 10,410 shares.
• Several analysts have upgraded GeneDx, with a consensus rating of "Moderate Buy" and an average target price of $101.63.
• The company reported a surprising $0.50 EPS in its latest earnings, well above the $0.10 consensus estimate, with revenues reaching $102.69 million.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $135.39 and last traded at $134.75, with a volume of 10410 shares. The stock had previously closed at $132.54.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on WGS shares. Piper Sandler lifted their price target on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Finally, Guggenheim restated a "buy" rating and issued a $115.00 target price (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $104.13.

GeneDx Trading Down 1.5%

The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of 2,479.00 and a beta of 2.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.87 and a quick ratio of 2.70. The business's 50-day simple moving average is $106.99 and its two-hundred day simple moving average is $91.80.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million for the quarter, compared to analysts' expectations of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. On average, research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In other news, Director Jason Ryan sold 38,072 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the transaction, the director directly owned 103,284 shares of the company's stock, valued at approximately $13,148,053.20. The trade was a 26.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 5,278 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total transaction of $490,854.00. Following the transaction, the chief financial officer directly owned 3,392 shares in the company, valued at approximately $315,456. The trade was a 60.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 561,641 shares of company stock valued at $67,551,904. 29.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. acquired a new position in shares of GeneDx during the fourth quarter worth $2,645,000. Raymond James Financial Inc. lifted its position in shares of GeneDx by 25.8% during the first quarter. Raymond James Financial Inc. now owns 333,376 shares of the company's stock worth $29,525,000 after purchasing an additional 68,331 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of GeneDx by 22,194.3% during the first quarter. GAMMA Investing LLC now owns 38,792 shares of the company's stock worth $3,436,000 after purchasing an additional 38,618 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of GeneDx by 111.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 190,297 shares of the company's stock worth $16,097,000 after purchasing an additional 100,146 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of GeneDx by 1.6% during the fourth quarter. Nuveen Asset Management LLC now owns 197,365 shares of the company's stock worth $15,169,000 after purchasing an additional 3,084 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.